skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Hematopoietic stem cell transplantation

Review

(2966) Views  (1153) Full article downloads

Authors: Eleftheria Hatzimichael, Mark Tuthill

Published Date August 2010 Volume 2010:3 Pages 105 - 117
DOI: http://dx.doi.org/10.2147/SCCAA.S6815

Eleftheria Hatzimichael1, Mark Tuthill2
1Department of Haematology, Medical School of Ioannina, University of Ioannina, Ioannina, Greece; 2Department of Medical Oncology, Hammersmith Hospital, Imperial College National Health Service Trust, London, UK

Abstract: More than 25,000 hematopoietic stem cell transplantations (HSCTs) are performed each year for the treatment of lymphoma, leukemia, immune-deficiency illnesses, congenital metabolic defects, hemoglobinopathies, and myelodysplastic and myeloproliferative syndromes. Before transplantation, patients receive intensive myeloablative chemoradiotherapy followed by stem cell “rescue.” Autologous HSCT is performed using the patient’s own hematopoietic stem cells, which are harvested before transplantation and reinfused after myeloablation. Allogeneic HSCT uses human leukocyte antigen (HLA)-matched stem cells derived from a donor. Survival after allogeneic transplantation depends on donor–recipient matching, the graft-versus-host response, and the development of a graft versus leukemia effect. This article reviews the biology of stem cells, clinical efficacy of HSCT, transplantation procedures, and potential complications.

Keywords: hematopoietic stem cell transplantation, complications







Readers of this article also read:
  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University